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Aims and methods
Glypican 3 (GPC3) belongs to the glypican family of GPI
anchored heparan sulfate proteoglycans, which play a cru-
cial role in cellular growth, cell migration and cell differ-
entiation. Several studies have shown GPC3 to be a highly
specific marker for hepatocellular carcinoma (HCC) and
for differentiating non- and pre-neoplastic liver disease.
To systematically investigate the epidemiology of GPC3
expression in non-neoplastic, pre-neoplastic and neoplas-
tic tissues, we used tissue microarray (TMA) technology to
analyze the immunohistochemically detectable expres-
sion of GPC3 in 3,678 tissue samples from 132 different
tumor categories and 31 non-neoplastic and pre-neoplas-
tic tissue types.
Furthermore, GPC3 expression was investigated in an
additional TMA containing 405 non-neoplastic, pre-neo-
plastic and neoplastic liver samples.
Results
GPC3 expression was found in 23% of non-neoplastic
(liver cirrhosis), in 37% of pre-neoplastic (low- and high-
grade dysplastic nodules) and in 64% of neoplastic liver
disease. Furthermore, testicular non-seminomatous germ
cell tumors (55%), squamous cell carcinoma of the lung
(54%), liposarcoma (52%), cervical intraepithelial neo-
plasia (CIN) III (41%), melanoma (29%) and schwan-
noma (26%) also revealed consistent expression of GPC3.
Conclusion
This study provides a comprehensive overview on the
expression of GPC3 in normal and cancerous tissue.
Among neoplastic tissue, our data underline the role of
GPC3 in hepatocellular carcinogenesis and suggest a
potential role of GPC3 as a therapeutic target in these
tumors. Moreover, several non-hepatic tumors can also
show GPC3 positivity.
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